CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 155 enrolled
Drug / intervention
KP415 oral capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03292952
NCT03292952Phase 3Completed
CompareCT.gov

A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder

Zevra Therapeutics·interventional·Posted Sep 26, 2017·Updated Jun 30, 2021

In Brief

A Phase 3 clinical trial evaluating KP415 oral capsule and Placebo oral capsule for ADHD. Completed, enrolled 155 participants across 5 sites.

Detailed Summary

The study is a multicenter, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy laboratory classroom study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 26, 2017
Enrollment StartDec 20, 2017
Primary CompletionMay 16, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.8 years ago

Interventions

KP415 oral capsuledrug

Daily dose

Placebo oral capsuledrug

Daily dose